Efficacy and Safety of Intravitreal Bevacizumab in the Treatment of Choroidal Neovascular Membranes Associated to High Myopia

Inclusion Criteria: * Patient at least 18 years old * High Myopia with one of the following: * 6 or more sphere diopters in the study eye * Axial length of the eye greater than 26 millimeters * Active subfoveal/juxtafoveal choroidal neovascularization confirmed by Fluorescein angiography and Ocular coherence tomography. * Visual acuity loss of less than 6 months of evolution related to the neovascular lesion, as stated by investigator´s opinion. * Patients previously treated with Photodynamic therapy are allowed to participate as long as the last treatment has been performed more than 3 months upon entering the study. * Signed informed consent. * Signed data protection consent. * Women of childbearing potential must provide a negative pregnancy test at inclusion and must commit to the use of a contraceptive treatment during the whole study. Exclusion Criteria: * Previous vitrectomy surgery in the study eye. * Tractional maculopathy and/or epiretinal membrane evaluated by Ocular coherence tomography. * Opacities that may not allow correct fundus assessment. * Lack of integrity of the posterior lens capsule in pseudoaphakic patients. * Patients that may not want/be able to complete the study, based in the investigator opinion.